Affymax, Inc.  

(Public, OTCMKTS:AFFY)   Watch this stock  
Find more results for NASDAQ:AFFY
0.137
-0.003 (-2.42%)
Jan 30 - Close
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range 0.14 - 0.14
52 week 0.08 - 1.09
Open 0.14
Vol / Avg. 56,514.00/149,018.00
Mkt cap 5.14M
P/E 1.91
Div/yield 0.05
EPS 0.07
Shares 37.49M
Beta 2.49
Inst. own 0%

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin 17164.29% -1053.62%
Operating margin -2269.05% -1099.05%
EBITD margin - -2724.25%
Return on average assets 488.14% -22.96%
Return on average equity 2040.59% -420.95%
Employees 4 -
CDP Score - -

Address

Suite 240, 19200 Stevens Creek Blvd
CUPERTINO, CA 95014
United States - Map
+1-650-8128700 (Phone)
+1-650-4240832 (Fax)

Website links

Description

Affymax, Inc. is a biopharmaceutical company. The Company�s product OMONTYS (peginesatide) is for the treatment of anemia due to chronic kidney disease in adult patients on dialysis. OMONTYS is a synthetic, peptide-based erythropoiesis stimulating agent (ESA), designed to stimulate production of red blood cells. The Company has a collaboration to develop and commercialize peginesatide with Takeda Pharmaceutical Company Limited. In March 2012, the Food and Drug Administration (FDA) approved the Company�s product, OMONTYS.

Officers and directors

John A. Orwin Independent Chairman of the Board
Age: 49
Jonathan M. Couchman President, Chief Executive Officer, Director
Age: 43
Mark G. Thompson Chief Financial Officer
Age: 53
Grace U. Shin General Counsel
Age: 48